Cannara Biotech, Inc. LOVE

The new financing structure provides greater financial flexibility through an expanded $40 million revolving credit facility, reduced borrowing costs and an extended maturity to December 31, 2029MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., t

MONTREAL, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., announced today that, in connection with its previously announced normal course issuer bid (“NCIB”) to purchase up to 1,975,642 of its common shares (“Shares”) during the twelve-month period commen

MONTREAL, July 22, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0),a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to proceed with a normal course issuer bid ("NCIB"). Pursuant to the NCIB, Cannara may purchase up to 1,9

Cannara Biotech Inc (LOVFF) reports a 16% increase in gross cannabis revenue and secures a significant international supply agreement with Curaleaf.

Delivered strong Q3 financial results: Generated $31.8 million in total net revenues, $13.4 million in gross profit before fair value adjustments, or 42% of revenues, $8.5 million in adjusted EBITDA1, and $5.7 million in operating cash flow.Expanded national distribution and retail penetration: Cannara products exceeded 49,000 points of distribution as of June 2026 and represented an estimated 3.3% of total cannabis product retail listings nationally, up from 3.1% during Q3 2026, 3.0% in Q2 2026

MONTREAL, July 08, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., today announced that it will release its financial results for the fiscal third quarter ended May 31, 2026, on Wednesday, July 15, 2026, at 8:00 AM ET. Cannara Biotech Chief Operating Officer and I

Cannara Biotech (LOVE.TO) on Thursday said it entered into an exclusive agreement with Blue River of

Partnership combines Cannara's leadership in premium solventless cannabis with Blue River's proprietary infusion technology to bring a new generation of live rosin products to Canadian consumersMONTREAL, July 02, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities in Québec spanning over 1,600,000 sq. ft., tod

The Canadian market has shown resilience, with 2026 TSX earnings growth projections being revised higher, supported by robust energy and materials sectors alongside strong technology earnings in the U.S. Despite potential challenges such as elevated oil prices and inflationary pressures, the underlying fundamentals of the Canadian economy remain solid. In this context, penny stocks—often associated with smaller or newer companies—continue to offer intriguing opportunities for investors...

As global markets navigate geopolitical tensions and economic shifts, Canadian stocks have shown resilience, with investors increasingly focusing on underlying fundamentals. In this context, penny stocks—often representing smaller or emerging companies—continue to intrigue due to their potential for growth when supported by strong financials. This article will explore three such TSX-listed penny stocks that stand out for their stability and growth prospects in today's market landscape.

With major U.S. equity benchmarks recently hitting new record highs, the focus has shifted from geopolitical tensions to underlying economic and corporate fundamentals. In this context, penny stocks—once a buzzword but now more of a niche investment area—continue to attract attention for their potential growth opportunities, especially when backed by strong financial health. This article will explore several Canadian penny stocks that stand out for their financial strength and long-term...

As global markets react to geopolitical tensions and economic signals, the focus has shifted back to fundamental economic indicators, with recent improvements in the U.S. labor market providing a positive backdrop. In such a climate, investors often seek opportunities that balance potential gains with financial stability. Penny stocks, despite their somewhat antiquated name, represent smaller or newer companies that can offer significant value when underpinned by strong financials. This...

The Canadian market has been experiencing a period of growth, driven by strong corporate earnings that are counterbalancing challenges such as rising energy prices and inflation pressures. Amidst this backdrop, penny stocks—often smaller or newer companies—continue to capture the interest of investors looking for unique opportunities outside the mainstream. While the term "penny stocks" may seem outdated, these investments can offer significant potential when backed by robust financials and...

The Canadian market has been navigating a complex landscape, with strong corporate earnings offsetting challenges such as higher energy prices and inflation pressures. In this context, penny stocks—typically smaller or newer companies—remain an intriguing area for investors seeking growth opportunities at lower price points. Despite their vintage name, these stocks can offer hidden value and potential upside when backed by solid financial foundations and robust fundamentals.

The Canadian market has shown resilience with strong corporate earnings offsetting challenges from rising energy prices, inflation pressures, and central bank uncertainties. For investors interested in exploring smaller or newer companies, penny stocks—despite their somewhat outdated name—remain a relevant investment area offering potential value. These stocks can provide growth opportunities at lower price points when backed by solid financial health and fundamentals.

The Canadian market has been navigating a complex landscape, where strong corporate earnings are counterbalancing challenges from higher energy prices and inflation pressures. In this environment, understanding the potential of penny stocks becomes increasingly relevant. While often seen as remnants of past market eras, penny stocks can still offer significant growth opportunities when backed by robust financials and strategic positioning.

The Canadian market has recently shown resilience, with strong corporate profits offsetting challenges like higher energy prices and inflation pressures. For investors looking beyond the major players, penny stocks—often representing smaller or newer companies—can offer intriguing opportunities. While the term "penny stock" might seem outdated, these stocks remain relevant by potentially combining affordability with growth prospects when backed by solid financials.

The Canadian market has shown resilience, with strong corporate earnings offsetting challenges from higher energy prices and inflation pressures. As investors navigate these complex conditions, penny stocks—despite their somewhat outdated name—remain a compelling area for those seeking opportunities in smaller or newer companies. By focusing on financial strength and growth potential, these stocks can offer hidden value and the possibility of outsized returns.

MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, the “Company”, “us” or “we”) (TSX: LOVE) (OTCQX: LOVFF) (FRA: 8CB0), a vertically integrated producer of premium-grade cannabis products at affordable prices, with two mega facilities based in Québec spanning over 1,600,000 sq. ft., today announced the closing of a transaction to acquire all of the shares of Medican Organic Inc. (“Medican”), a wholly owned subsidiary of BZAM Ltd., for an aggregate purchase price of $2.8